Discrimination analysis of blood plasma associated with Alzheimer's disease using vibrational spectroscopy

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 911-920

  Carmona, Pedro ^a   Molina, Marina ^b   Calero, Miguel ^c,d   Bermejo Pareja, Félix ^d,e   Martínez Martín, Pablo ^d   Toledano, Adolfo ^f  

^a INSTITUTO DE ESTRUCTURA DE LA MATERIA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f INSTITUTO CAJAL   (Spain)

Author keywords

Alzheimer's disease; biomarker; diagnosis; infrared spectroscopy; Raman spectroscopy

Indexed keywords

AGED; AGING; ALPHA HELIX; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE ASSOCIATION; EXCITATION; FEMALE; HUMAN; INFRARED SPECTROSCOPY; LASER; MALE; NEAR INFRARED SPECTROSCOPY; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RAMAN SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SPECTROMETER; SPECTROSCOPY; VIBRATIONAL SPECTROSCOPY;

EID: 84876349832     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122041     Document Type: Article

References (44)

1. Kelley BJ, Petersen RC (2007) Alzheimer's disease and mild cognitive impairment. Neurol Clin 25, 577-609. (Pubitemid 47058874)
2. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. J Neurochem 97, 1700-1725. (Pubitemid 43873662)
3. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4, 38-48.
4. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, TsuiW, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H,Wahlund L-O, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401. (Pubitemid 43185324)
5. Bermejo-Pareja F, Antequera D, Vargas T, Molina JA, Carro E (2010) Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: A pilot study. BMC Neuro 10, 108.
6. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80.
7. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050. (Pubitemid 44684524)
8. Schrader B (1995) Infrared and Raman Spectroscopy: Methods and Applications, Verlag Chemie, Weinheim.
9. Carmona P, Molina M, Calero M, Bermejo-Pareja F, Martínez- Martín P, Alvarez I, Toledano A (2012) Infrared spectroscopic analysis of mononuclear leukocytes in peripheral blood from Alzheimer's disease patients. Anal Bioanal Chem 402, 2015-2021.
10. Chen P, Tian Q, Baek SJ, Shang XL, Park A, Liu ZC, Yao XQ,Wang JZ,Wang XH, Cheng Y, Peng J, Shen AG, Hu JM (2011) Laser Raman detection of platelet as a non-invasive approach for early and differential diagnosis of Alzheimer's disease. Laser Phys Lett 8, 547-552.
11. Griffiths PR, Chalmers JM, Pivonka DE (2007) History, trends and prognostications. In Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development. Pivonka DE, Chalmers JM, Griffiths (eds). JohnWiley, Chichester, pp. 353-362.
12. Maguregui M, Knuutinen U, Trebolazabala J, Morillas H, Castro K, Martinez-Arkarazo I, Madariaga JM (2012) Use of in situ and confocal Raman spectroscopy to study the nature and distribution of carotenoids in brown patinas from a deteriorated wall painting in Marcus Lucretius House (Pompeii). Anal Bioanal Chem 402, 1529-1539.
13. Peuchant E, Richard-Harston S, Bourdel-Marchasson I, Dartigues JF, Letenneur L, Barberger-Gateau P, Arnaud-Dabernat S, Daniel JY (2008) Infrared spectroscopy: A reagent-free method to distinguish Alzheimer's disease patients from normal-aging subjects. Transl Res 152, 103-112.
14. Burns DH, Rosendahl S, Bandilla D, Maes OC, Chertkow HM, Schipper HM (2009) Near infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer's disease. J Alzheimers Dis 17, 391-397.
15. Liao P-C,Yu L,Kuo C-C, Lin C,KuoY-M (2007) Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin Appl 1, 506-512.
16. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922. (Pubitemid 27008725)
17. Calero M, Rostagno A, Ghiso J (2012) Search for amyloidbinding proteins by affinity chromatography. Methods Mol Biol 849, 213-223.
18. Mackhann G, Drachman D, Folstein M, Katzman R, Proce D, StadlanEM(1984) Clinical diagnosis of Alzheimer's disease. Neurology 34, 939-944.
19. Reisberg B, Ferris SH, DeLeon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiat 139, 1136-1139. (Pubitemid 12051593)
20. Tuma R (2005) Raman spectroscopy of proteins: From peptides to large assemblies. J Raman Spectrosc 36, 307-319. (Pubitemid 40653528)
21. Krimm S, Bandekar J (1986) Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv Protein Chem 38, 181-363.
22. Noda I, Ozaki Y (2004) Principle of two-dimensional correlation spectroscopy. In Two-dimensional Correlation Spectroscopy. Applications in Vibrational and Optical Spectroscopy, John Wiley, Chichester, United Kingdom.
23. McIntosh LM, Summers R, Jackson M, Mantsch HH, Mansfield JR,Howlett M, Crowson AN,TooleJWP(2001)Towards non-invasive screening of skin lesions by near-infrared spectroscopy. J Invest Dermatol 116, 175-181. (Pubitemid 32108769)
24. Nijssen A, Schut TCB, Heule F, Caspers PJ, Hayes DP, Neumann MH, Puppels GJ (2002) Discriminating basal cell carcinoma from its surrounding tissue by Raman spectroscopy. J Invest Dermatol 119, 64-69. (Pubitemid 35304392)
25. Stone N, Kendall C, Shepherd N, Crow P, Barr H (2002) Near-infrared Raman spectroscopy for the classification of epithelial pre-cancers and cancers. J Raman Spectrosc 33, 564-573.
26. Barth A, Zscherp C (2002) What vibrations tell us about proteins. Quart Rev Biophys 35, 369-430. (Pubitemid 36207229)
27. Harada I, TakeuchiH(1986) Raman and ultraviolet resonance Raman spectra of proteins and related compounds. In Spectroscopy of Biological Systems, Clark RJH, Hester RE (eds). John Wiley, Chichester 113-175.
28. Maruyama T, Takeuchi H (1995) Effects of hydrogen bonding and side-chain conformation on the Raman bands of tryptophan-2,4,5,6,7-d5. J Raman Spectrosc 26, 319-324.
29. Montuschi P, Barnes PJ, Roberts LJ (2004) Isoprostanes: Markers and mediators of oxidative stress. FASEB J 18, 1791-1800. (Pubitemid 39602265)
30. Socrates G (2001) Hydroxyl group compounds: O-H group. In Infrared and Raman Characteristic Group Frequencies: Tables and Charts. Socrates G (ed), John Willey, England, pp. 94-100.
31. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczu P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VMY, Shaw LM, the Alzheimer's Disease Neuroimaging Initiative (2010) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6, 230-238.
32. Qiu C (2012) Preventing Alzheimer's disease by targeting vascular risk factors: Hope and gap. J Alzheimers Dis 32, 721-731.
33. Sperling RA, Jack CR JR, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3, 111-133.
34. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213, 96-103.
35. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89, 807-811. (Pubitemid 38684728)
36. Kawarabayashi T, Shoji M (2008) Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry 21, 260-267. (Pubitemid 351489346)
37. Whisstock JC, Skinner R, Carrell RW, Lesk AM (2000) Conformational changes in serpins: I. The native and cleaved conformations of α1-antitrypsin J Mol Biol 296, 685-699.
38. Griffiths PR (2007) Introduction to vibrational spectroscopy. In Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development. Pivonka DE, Chalmers JM, Griffiths (eds). John Wiley, Chichester, pp. 3-16.
39. Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040. (Pubitemid 350057358)
40. Montine TJ, Quinn J, Kaye J, Morrow JD (2007) F(2)- isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci 33, 114-119. (Pubitemid 47574948)
41. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48, 809-812.
42. Quinn JF, Montine KS, Moore M, MorrowJD, Kaye JA,Montine TJ (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6, 93-97. (Pubitemid 38418561)
43. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, Nunomura A, Zhu X, Smith MA, PerryG(2005) Oxidative stress: The old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res 2, 403-440.
44. Yu H-L, Chertkow HM, Bergman H, Schipper HM (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3, 2240-2248. (Pubitemid 37414088)